Statement of Principles concerning transverse myelitis (Reasonable Hypothesis) (No. 71 of 2021)

The instrument’s central legal concept is the "reasonable hypothesis" connecting transverse myelitis or death from transverse myelitis to relevant service. The instrument does not define "reasonable hypothesis" but sets the minimum medical factors which, if present and related to relevant service, are to be taken as sufficient to raise that hypothesis (s 8). Those factors are discrete clinical, exposure and treatment items with specific temporal windows in relation to the clinical onset of TM, for example infections within two months, heroin within seven days, or drugs on the specified list within two months (s 8(1)-(8)).

Transverse myelitis is defined substantively here rather than solely by ICD coding. Subsection 6(2) frames TM as an acute or subacute immune‑mediated inflammatory disorder of the spinal cord producing impaired motor, sensory or autonomic functioning, and lists multiple categories of myelopathy that are excluded from this Statement (s 6(2)(a)-(b)). Two diagnostic notes accompany subsection 6(2): one summarises typical clinical presentation (symptoms over hours to days, bilateral sensory alteration, defined upper sensory level, possible bowel/bladder dysfunction) and the other points to confirmation by neuroimaging or cerebrospinal fluid analysis (s 6 note 1; s 6 note 2). The instrument also recognises the ICD‑10‑AM code G37.3 but clarifies that the statutory meaning is the text in subsection 6(2) (ss 6(3)-(4)).

The Schedule supplies operative definitions that shape the reach of the factors. "Relevant service" is defined to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (schedule). "Specified list of drugs" is a narrow category: biologic agents for the treatment of cancer or tumour necrosis factor‑α inhibitors (schedule). "Biologic agent" is defined and the Schedule gives examples (for instance tyrosine kinase inhibitors, immune checkpoint inhibitors and dinutuximab). The schedule also defines "terminal event" by listing proximate or ultimate causes of death that may be contributed to by TM (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).

Relationship to service is a separate, mandatory requirement: the existence of any factor listed in section 8 must be related to the person’s relevant service (s 9(1)). The treatment‑availability factor (inability to obtain appropriate clinical management) has its own limitation: it only operates as a possible material contribution or aggravation where the TM was suffered or contracted before or during (but did not arise out of) relevant service (s 9(2); s 8(10)). Section 10 governs cross‑references: where a factor in section 8 refers to an injury or disease covered by another Statement of Principles, the factors in that other Statement apply according to their terms as in force from time to time (s 10).

Finally, the instrument is procedural and definitional rather than punitive: it sets thresholds for claims determination. It specifies temporal windows and categorical exclusions that will materially affect how evidence is gathered and how causation is framed in claims adjudication.

Primary affected parties are veterans, members of Peacekeeping Forces, and members of the Forces whose claims fall within the operation of section 120A of the VEA or section 338 of the MRCA (s 4; schedule definition of relevant service). The instrument itself is framed to be applied to claims by those persons seeking a connection between transverse myelitis (or death from it) and their relevant service. It therefore affects:

• Claimants: individuals who have been diagnosed with, or died from, TM and who seek a reasonable hypothesis that links that condition to their relevant service. To meet the instrument’s threshold, claimants must establish that at least one enumerated factor existed as a minimum (s 8) and that it was related to their relevant service (s 9(1)).

• Medical practitioners and treating clinicians: because diagnosis and the documentation that underpins a claim are medical in nature. The instrument explicitly notes that diagnosis can be confirmed by neuroimaging or CSF analysis (s 6 note 2); practitioners will therefore be the source of the diagnostic evidence that claimants supply.

• Claims decision‑makers under the VEA and MRCA regimes: administrators responsible for applying section 120A VEA or section 338 MRCA will use this Statement as the medical yardstick for whether a reasonable hypothesis has been raised. The instrument is made by the Repatriation Medical Authority to guide that adjudication (s 3).

• Service record holders and administrative staff: because the instrument requires a relationship between the factor and relevant service (s 9(1)), evidence drawn from service records, vaccination records, deployment logs or other administrative materials may be necessary to demonstrate that relationship.

• Oncology and pharmacology stakeholders: the Schedule’s inclusion of biologic agents and tumour necrosis factor‑α inhibitors as the "specified list of drugs" (schedule) means that persons who received such therapies , particularly biologic agents used for cancer , are affected when those therapies are within the temporal window specified (s 8(6); schedule).

• Transplant recipients: the instrument lists bone marrow or stem cell transplant as a factor (s 8(9)), so those who received those procedures prior to TM onset are potentially affected.

Indirectly, other parties affected include insurers and legal practitioners (who prepare and advise on claims), and health services responsible for providing clinical management where "inability to obtain appropriate clinical management" is invoked (s 8(10); s 9(2)). The instrument’s exclusions (s 6(2)(b)) mean that persons with spinal cord disease attributable to specifically listed causes (for example multiple sclerosis, neuromyelitis optica syndrome, tumour invasion, trauma, radiation) will generally not meet the instrument’s definition of TM for the purpose of raising a reasonable hypothesis under this Statement.

The instrument does not itself create monetary liability, penalties, or a payment mechanism. It operates within the entitlement frameworks of the VEA and MRCA; thus it affects the pathway by which affected persons may secure entitlements under those Acts (s 4).

The instrument imposes no criminal or statutory fines, but it creates procedural duties on decision‑makers and practical evidentiary duties on claimants and medical practitioners.

Duties on decision‑makers:

• Apply the Statement as the medical benchmark in determining whether a reasonable hypothesis has been raised connecting TM or death from TM with the circumstances of a person’s relevant service (s 8; s 3). The instrument constitutes the Repatriation Medical Authority’s determination under subsection 196B(2) of the VEA (s 3).
• Where a factor in section 8 refers to an injury or disease that is the subject of another Statement of Principles, decision‑makers must apply the factors in that other Statement according to its terms as currently in force (s 10).

Duties on claimants and their advisers (practical duties implied by the instrument’s structure):

• Establish that at least one enumerated factor exists before it can be said that a reasonable hypothesis has been raised (s 8). Each factor generally requires evidence about timing and clinical status relative to the clinical onset of TM.
• Demonstrate that any such factor is related to the person’s relevant service (s 9(1)). This requires connecting the factor (for example, an infection or exposure, vaccination, or inability to obtain treatment) with the nature or circumstances of the person’s relevant service as defined in the Schedule.
• Where factor 8(10) (inability to obtain appropriate clinical management) is relied upon, ensure the condition of timing is satisfied: the person’s TM must have been suffered or contracted before or during the relevant service and must not have arisen out of the relevant service; this factor applies only to material contribution to, or aggravation of, TM in that circumstance (s 9(2)).

Rights implicit in the instrument:

• Claimants have the procedural right to have their claim assessed against the medical criteria set out in this Statement. The instrument specifies the factors that operate to raise a reasonable hypothesis (s 8), and claimants whose medical and service facts satisfy those factors have the basis for asserting that a reasonable hypothesis has been raised.
• Where a factor refers to a disease or injury addressed in another Statement of Principles, claimants benefit from the cross‑reference: the other Statement’s factors apply by their terms (s 10).

Medical documentation duties:

• The instrument explicitly identifies neuroimaging or cerebrospinal fluid analysis as confirmatory diagnostics for TM (s 6 note 2). Thus claimants and practitioners must ensure that those objective diagnostic records are obtained and presented where available.

Limitations and exclusions that constrain rights:

• The instrument narrows what counts as TM for these purposes and explicitly excludes several other myelopathies and etiologies (s 6(2)(b)). A claimant whose spinal cord disorder falls within an excluded category will not meet the definition of TM in this Statement, which limits access to a reasonable‑hypothesis finding under this instrument.
• The Schedule’s definitions shape who is covered. Relevant service is defined to particular categories of VEA and MRCA service (schedule). A person’s service must fall within those categories for this Statement to apply to their claim (s 4; schedule).

The instrument is a technical medical benchmark that produces duties primarily in evidence production and decision‑making rather than new statutory obligations on the wider public.

The Statement of Principles itself does not create offences, penalties, or enforcement mechanisms in the form of fines or criminal sanctions. The instrument is directional and evidentiary: it prescribes medical factors and definitions that decision‑makers must use when deciding whether a reasonable hypothesis has been raised linking transverse myelitis or death from transverse myelitis with the circumstances of a person’s relevant service (ss 3-4; s 8). There are no provisions in the instrument that impose civil penalties, regulatory sanctions or enforcement powers.

Enforcement in practice is administrative and embedded in the claims process. The instrument will be used by those adjudicating claims under the VEA and the MRCA , that is, the statutory decision‑makers operating under section 120A of the VEA or section 338 of the MRCA as identified in section 4. Compliance with the instrument’s requirements will therefore be enforced by the effect they have upon claims outcomes: if the minimum factors in section 8 are not established and related to relevant service under section 9, a decision‑maker will not be able to accept that a reasonable hypothesis is raised, which in turn affects entitlement decisions under the VEA and MRCA framework.

There is one implicit procedural limit that functions like a rule of evidentiary scope: where a factor in section 8 refers to an injury or disease for which another Statement of Principles exists, the other Statement applies according to its terms (s 10). This operates as an administrative cross‑reference that channels the assessment of particular causal pathways through the relevant Statement.

Because the instrument is made under subsection 196B(2) of the VEA (s 3), its practical enforcement is through the administrative decision‑making and dispute resolution mechanisms that the VEA and MRCA provide. The Statement itself contains no investigatory powers, disciplinary regimes, penalty schedules or criminalising provisions. Any enforcement consequences arise from the administrative determination of entitlements under the VEA or MRCA rather than from this instrument imposing separate sanctions.

This Statement of Principles is expressly made under the Veterans' Entitlements Act 1986 and applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (ss 3-4). It is therefore a statutory medical instrument designed to be read and applied within the VEA/MRCA entitlement frameworks.

Interaction with the VEA and MRCA:

• The Statement is a medical determination under subsection 196B(2) of the VEA (s 3). Its purpose is to produce the medical criteria used in adjudicating whether a reasonable hypothesis exists connecting a disease or death with relevant service. The Statement therefore feeds directly into decision‑making performed under the VEA and MRCA provisions cited in section 4.

Cross‑Statement interaction:

• Section 10 creates an explicit interaction with other Statements of Principles. If a factor in section 8 refers to an injury or disease that is itself the subject of another Statement made under subsection 196B(2) of the VEA, then the factors in that other Statement apply in accordance with its terms as in force from time to time. This means that when an 8-series factor invokes a separate disease entity, the assessment may require applying that other Statement’s medical factors and temporal criteria (s 10).

ICD coding and clinical definition:

• The instrument refers to the ICD‑10‑AM code G37.3 for TM but disclaims that the statutory meaning is the text in subsection 6(2) (ss 6(3)-(4)). The ICD reference links to the broader health classification regime (The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification), but the instrument clarifies that claim assessment should be guided by the express statutory definition rather than by coding alone.

Interaction with clinical practice standards:

• The instrument identifies diagnostic confirmation by neuroimaging or cerebrospinal fluid analysis (s 6 note 2). This links the instrument to accepted clinical diagnostics, meaning medical evidence produced under clinical practice standards becomes relevant evidence in VEA/MRCA claim assessments.

Interaction with administration of vaccines and pharmaceuticals:

• Several section 8 factors turn on exposure to vaccines, drugs, or illicit substances within specified time windows (for example, oral polio vaccine within two months at s 8(8); specified list of drugs within two months at s 8(6); heroin within seven days at s 8(7)). The Schedule defines the "specified list of drugs" narrowly as biologic agents for cancer or TNF‑α inhibitors. Thus, assessments under this Statement will interface with medical records, pharmaceutical dispensing records and possibly public‑health vaccination records. The instrument does not, however, create regulatory obligations on manufacturers or health providers; it simply uses exposure information as a causation factor for claims purposes.

Relationship to service records and entitlement law:

• The Schedule defines "relevant service" by reference to categories under the VEA and MRCA. The instrument therefore interacts with the body of law and administrative practice that determines whether a particular period or nature of service satisfies those definitions. The Statement does not alter the legal definitions of relevant service; it operates once that status is established for the claimant’s service.

In summary, the instrument is a specialised medical standard that sits within the VEA/MRCA claims framework, cross‑references other Statements of Principles where relevant, and relies upon clinical and administrative records (diagnostic imaging, CSF, medication/vaccination records, service records) to operationalise its factors. It does not itself amend the substantive entitlements in the VEA or MRCA, but it materially shapes how causation is assessed in claims under those Acts.

The instrument expressly states its name and identifies itself as Statement of Principles concerning transverse myelitis (Reasonable Hypothesis) (No. 71 of 2021) (s 1). It records that it was dated 21 May 2021 and that it commences on 21 June 2021 (s 1; s 2). The instrument is made under subsection 196B(2) of the VEA (s 3). The text provided does not include any subsequent amendments or repeal provisions, nor does it show prior versions. As supplied, the instrument is a stand‑alone Statement determined in 2021.

What the instrument records about its provenance and effect:

• It is determined by the Repatriation Medical Authority (RMA). The instrument bears the RMA’s seal and the direction of the RMA’s Chairperson as the procedural formality verifying that the Authority made the determination (heading material).
• The commencement date is explicitly set one month after the date on the instrument: dated 21 May 2021, commencement 21 June 2021 (ss 1-2).

No amendment entries or schedules of amendment are present in the text provided. There are no transitional provisions or grandfathering clauses included in this instrument itself. The instrument contains a cross‑reference mechanism (s 10) by which factors that refer to other diseases are subject to other Statements "as in force from time to time". That cross‑reference means that while this instrument as made in 2021 may remain static until amended, its practical application can be affected by subsequent changes to other Statements of Principles that it relies upon.

Where amendments would occur in future practice:

• Any later amendments to this Statement would be effected by the Repatriation Medical Authority under the same statutory power (subsection 196B(2) of the VEA), and would be documented as a new version or amending instrument. The instrument itself contains no procedural description of how RMA will amend it, but that power is the statutory source for the instrument (s 3).

Given the absence of amendment history in the supplied text, practitioners should treat this instrument as the 2021 determination and check the RMA's official registers or the Government Gazette for any subsequent amending instruments or reissued versions when advising clients or preparing claims.

The instrument itself contains no citations to judicial decisions, and the text supplied does not record any litigation history dealing with the instrument’s provisions. No cases are named in the instrument, and there is no reference to legal challenges, declaratory proceedings, or judicial review concerning this particular Statement of Principles within the document.

Consequences of that absence for practitioners:

• Because the instrument, as supplied, does not refer to any case law, users must rely on the instrument’s text and its statutory provenance under subsection 196B(2) of the VEA (s 3) when applying it to claims. The lack of recorded litigation in the instrument means there is no in‑instrument authoritative judicial interpretation to guide how courts have construed these specific factors or the instrument’s operation. Where legal questions arise about the proper application of the Statement , for example, the scope of "related to relevant service" in s 9(1), or the evidentiary standards required to show an infection within two months in s 8(1) , resolution will rely on administrative decision‑making, internal tribunal or appeal processes available under the VEA and MRCA frameworks and, if taken further, judicial review and appellate decisions external to the instrument.

Practical implication for evidence and argument:

• Because there is no litigation history recorded in the instrument, parties preparing claims should focus on producing evidence that aligns clearly with the instrument’s textual criteria: diagnostic confirmation (s 6 note 2), the timing windows and categorical definitions in section 8, and the relationship to relevant service required by section 9. Absent settled judicial guidance specific to this instrument, persuasive administrative submissions and carefully documented medical evidence will be the primary means by which claimants demonstrate that a reasonable hypothesis has been raised.

Recommendation implicit in the absence of cases:

• Practitioners should check the broader case law and the administrative appeals record under the VEA and MRCA for general principles about how "reasonable hypothesis" and related causation concepts have been applied, but do so with the understanding that any such external jurisprudence is not cited in the instrument itself. For the purposes of applying this instrument, the text of the Statement and the statutory definitions in the Schedule will be the principal authorities to which a decision‑maker must attend.

The instrument contains several precise textual features and limitations that can produce traps for practitioners and claimants if overlooked. These "gotchas" are grounded in the instrument’s phrasing, timing windows, definitions and cross‑references.

1. Substantive definitional exclusion: transverse myelitis is defined narrowly and expressly excludes a list of specific spinal cord pathologies and causes (s 6(2)(b)). If a claimant’s spinal cord condition is due to any listed excluded cause (for example multiple sclerosis, neuromyelitis optica syndrome, spinal cord compression, tumour invasion, trauma, radiation), the disorder will not be treated as transverse myelitis under this Statement. Do not rely solely on ICD coding (s 6(3)); the statutory text in s 6(2) controls.

2. Diagnostic confirmation expectation: the instrument notes that diagnosis can be confirmed by neuroimaging or cerebrospinal fluid analysis (s 6 note 2). Absence of those objective investigations may weaken a claim that satisfies the Statement’s requirements, because the Statement anchors the TM concept to those clinical confirmations as typical means of diagnosis.

3. Time windows are tight and variable: many factors in s 8 require exposures within tight, specified temporal windows relative to the clinical onset of TM:

   • Infections or symptomatic gastrointestinal/respiratory infection within two months (s 8(1)-(2));
   • Specified drugs within two months (s 8(6));
   • Oral polio vaccine within two months (s 8(8));
   • Heroin within seven days (s 8(7)). Practitioners must ensure that timing is precisely documented; approximate timings risk failing to hit the statutory minimum.

4. Narrow definition of "specified list of drugs": the Schedule defines the specified list narrowly,biologic agents for the treatment of cancer, and tumour necrosis factor‑α inhibitors (schedule). Biologic agents used for non‑cancer indications (other than TNF‑α inhibitors) are not included in the specified list unless they meet the schedule’s definition. However the Schedule’s definition of biologic agent includes examples (tyrosine kinase inhibitors, immune checkpoint inhibitors, dinutuximab). Carefully map each drug to the schedule definitions rather than relying on broad therapeutic class labels.

5. Inability to obtain clinical management limited in scope: the factor at s 8(10) is not a freestanding causation pathway. Section 9(2) constrains it to cases where the person’s TM was suffered or contracted before or during relevant service but did not arise out of the relevant service; in that situation the inability to obtain appropriate clinical management can apply only to material contribution to, or aggravation of, TM. The consequence is that inability to obtain treatment cannot be claimed as a material contributor where the TM itself arose out of relevant service.

6. Cross‑reference to other Statements can redirect proof requirements: if a section 8 factor refers to an injury or disease that is already covered by another Statement, section 10 requires application of that other Statement’s factors as in force from time to time (s 10). This can change the documentary and temporal requirements claimants must meet. Identify any cross‑referenced disease and obtain the current text of its Statement.

7. Death claims are not limited to primary cause: s 6(5) and the schedule define death from TM as including death from a terminal event or condition that TM contributed to. The schedule lists examples of terminal events (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). For death claims, practitioners must show contribution, not necessarily that TM was the proximate sole cause.

8. "Related to the relevant service" is an independent requirement: establishing a listed factor is not sufficient by itself; the factor must be related to relevant service per s 9(1). The instrument does not provide a formula for that relationship; claimants must address the link between the factor and the service circumstances as defined in the Schedule.

9. Exclusion of non‑melanotic malignant neoplasm of the skin in cancer factor: s 8(5) allows malignant neoplasm, other than non‑melanotic malignant neoplasm of the skin, as a factor. If the only malignancy is a non‑melanotic skin cancer, that factor will not be satisfied.

10. ICD code caution: although the instrument notes that TM attracts ICD‑10‑AM code G37.3 (s 6(3)), it insists that the statutory meaning is the definition in s 6(2). An administrative record that merely lists the ICD code without corroborating clinical evidence that meets the textual definition (and excludes the excluded entities) may be insufficient.

11. Examples of biologic agents are illustrative not exhaustive: the schedule gives examples of biologic agents that have been associated with transverse myelitis (tyrosine kinase inhibitors, immune checkpoint inhibitors, dinutuximab). Practitioners should not assume the list is exhaustive; instead, map the actual drug to the schedule definition to determine whether it falls within the specified list.

12. Service categories matter: the Schedule’s definition of relevant service is categorical (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA; warlike and non‑warlike under the MRCA). If a person’s service does not fall into one of these categories, this Statement does not apply (s 4; schedule).

Awareness and mitigation of these gotchas requires careful review of clinical records, pharmacological histories, vaccination records, service records and precise temporal sequencing between clinical onset and exposures. The textual constraints in the instrument mean that close factual attention to timing, diagnostic confirmation, and exclusionary etiologies is essential.

To comply with the requirements of this Statement of Principles when preparing or assessing a claim, follow a document‑centric and temporally precise approach that aligns explicitly with the instrument’s criteria.

1. Confirm the statutory applicability

   • Verify that the claim falls within the VEA or MRCA pathways specified in section 4 by confirming the claimant’s service status and that the claim is one to which section 120A of the VEA or section 338 of the MRCA applies (s 4; schedule definition of relevant service).

2. Establish the clinical diagnosis of transverse myelitis under s 6(2)

   • Obtain neuroimaging (spinal MRI reports/images) and cerebrospinal fluid (CSF) analysis records where available, because the instrument notes these methods as means of confirmation (s 6 note 2).
   • Document the clinical presentation: acute/subacute onset over hours to days, impaired motor, sensory or autonomic functions, bilateral sensory alteration and defined upper sensory level as relevant (s 6(2); s 6 note 1).
   • Ensure the clinical diagnosis addresses and rules out the exclusion list in s 6(2)(b) (for example multiple sclerosis, neuromyelitis optica syndrome, spinal cord compression, tumour invasion, trauma, radiation, vascular or degenerative pathologies).

3. Map factual circumstances to the enumerated factors in section 8

   • For each factor in s 8, collect contemporaneous records and date‑verified evidence:
     • s 8(1)-(2): clinical notes, microbiology tests, pathology, GP records that record symptomatic gastrointestinal or respiratory infection or evidence of viral/bacterial/fungal/parasitic infection within two months of TM onset.
     • s 8(3)-(5): records confirming systemic autoimmune disease, sarcoidosis, or malignant neoplasm at the time of TM onset; for cancer, note the exclusion for non‑melanotic malignant neoplasm of the skin (s 8(5)).
     • s 8(6): a medication history with dispensing records and medical notes showing the person took a drug on the specified list within two months before TM onset. Use the Schedule to determine whether the drug is a biologic agent for cancer or a TNF‑α inhibitor (schedule).
     • s 8(7): evidence of heroin use within seven days before TM onset; contemporaneous clinical or arrest records, treatment notes or testing where available.
     • s 8(8): immunisation records showing oral polio vaccine within two months before TM onset.
     • s 8(9): surgical and transplant records indicating bone marrow or stem cell transplant prior to TM onset.
     • s 8(10): documentation showing inability to obtain appropriate clinical management and chronology showing the TM was suffered or contracted before or during relevant service and did not arise out of the relevant service (see s 9(2) for its limited application).

4. Demonstrate the relationship to relevant service (s 9)

   • Compile service records that tie the relevant exposure or inability to obtain care to the circumstances of the person’s service. For example, if asserting inability to obtain appropriate clinical management due to location, deployment circumstances, or service‑related restrictions, provide the service records and contemporaneous medical correspondence showing the causal nexus.
   • Where the factor is an exposure (infection, vaccine, drug), show how that exposure was related to the nature of the person’s relevant service (for example, via deployment‑related contacts, vaccination program during service, or service‑provided medication).

5. Address cross‑referenced Statements (s 10)

   • If any factor in s 8 refers to an injury or disease covered by another Statement, obtain and apply the current text of that other Statement of Principles, because s 10 requires applying that Statement’s factors as in force from time to time.

6. For death claims, establish contribution to terminal event

   • Where the claim concerns death from TM, assemble the death certificate, clinical notes, hospital records and any post‑mortem reports that show TM contributed to the terminal event (s 6(5); schedule definition of terminal event lists pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).

7. Prepare a succinct evidentiary narrative

   • Tie the clinical evidence, timing and service records together in a chronology that addresses each element the instrument requires: diagnosis that fits s 6(2); presence of at least one factor in s 8 within the specified temporal window; and a clear statement and supporting evidence showing the factor’s relationship to relevant service under s 9(1).
   • Where relying on s 8(10) (inability to obtain appropriate clinical management), explicitly document that TM was suffered or contracted before/during service and did not arise out of service, and explain how the lack of appropriate care materially contributed to or aggravated TM (s 9(2)).

8. Anticipate and respond to excluded causes and definitional limits

   • Pre‑empt administrative queries by addressing excluded causes listed in s 6(2)(b) and ensuring any alternate explanations are considered and, where possible, ruled out or reconciled in the medical opinion supplied.

9. Ensure drug classification under the Schedule

   • When a drug is invoked under s 8(6), confirm its classification under the Schedule. If the drug is a biologic agent or a TNF‑α inhibitor, provide manufacturer and indication information and dispensing history that aligns with the schedule’s definitions.

10. Seek appropriate medical opinion

• Obtain a contemporaneous treating medical practitioner’s report that links the clinical history to the factor(s) alleged and expressly addresses whether, in their opinion, the factor raises a reasonable hypothesis that TM was connected to the person’s relevant service. Ensure the opinion explains the medical basis for why the factor meets the instrument’s criteria and addresses alternative aetiologies listed in s 6(2)(b).

11. Record preservation and indexing

• Preserve and index all clinical, pharmacy, vaccination and service records. Given the tight timing windows in s 8, dated and authenticated records will be decisive in establishing whether a statutory temporal requirement is met.

12. Verify currentness of Statements and policy

• Because s 10 references other Statements "as in force from time to time", check for any updates to related Statements of Principles that may alter how cross‑referenced factors are treated.

Complying with the Statement requires precise factual assembly: diagnosis that meets the statutory definition, timely and verifiable evidence of a listed factor, and demonstrable connection of that factor to the person’s relevant service. The Statement supplies clear, enumerated thresholds; compliance is therefore a matter of aligning documentary and medical evidence to those thresholds.